BACKGROUND The Vessix Renal Denervation System (Boston Scientific, Marlborough, MA) consists of an over-the-wire low-pressure balloon catheter with an array of bipolar radiofrequency electrodes. Primary endpoint results of the REDUCE-HTN trial showed significant blood pressure reductions and a low major adverse event rate 6 months following treatment with the Vessix system. Office blood pressure measurements and safety monitoring continues through 2 years post-treatment.
RESULTS Among enrolled patients (N¼146), mean baseline office blood pressure was 182.4AE18.4/100.1AE14.0 mmHg and ambulatory blood pressure was 152.9AE15.2/87.5AE13.3 mmHg. Among 94 patients with 18 month data, mean office blood pressure was reduced to 157.2AE24.6/86.9AE14.8 mmHg; a reduction of 27.1AE20.4/11.2AE11.4 mmHg (P<.0001). Eighty percent of those (75/94) responded to treatment with a reduction in office systolic blood pressure !10 mmHg at 18 months. The rate of procedure-related serious adverse events was 5.6% at 6 months, with no new procedure-or devicerelated serious adverse events reported between 6 and 18 months of followup. Final 2-year efficacy and safety data will be available at the time of presentation.
CONCLUSIONS Eighteen-month data available to date from the REDUCE-HTN study support the safety and efficacy of renal denervation with the Vessix system to treat resistant hypertension, with potential for sustained blood pressure reductions through 2 years. BACKGROUND Renal sympathetic denervation (RDN) has been introduced as a possible treatment for resistant hypertension (RH); however, the largest trial to date has shown little benefit. Our aim was to compare renal denervation versus pharmacological therapy in patients with resistant hypertension in eight trials.
METHODS
We conducted a meta-analysis of prospective trials which randomized patients with resistant hypertension to renal denervation or pharmacological antihypertensive treatment alone and reported the pre-specified outcomes. Mantel Haenszel relative risks and mean differences were calculated using random effect models.
RESULTS Eight trials (N¼1011) met the inclusion criteria. At 6 months RDN was associated with greater reduction in 24-hour systolic blood pressure (SBP) (mean difference -3.21; 95% CI -5.19, -1.24; P¼0.001), and 24-hour diastolic blood pressure (DBP) (mean difference -1.60; 95% CI -2.76, -0.44; P¼0.007). RDN was also associated with a decrease in the number of antihypertensive medications compared to the control arm (mean difference -0.32; 95% CI -0.52, -0.11; P¼0.002). The mean difference in change between RDN and control was -7.69 mm Hg for office SBP (P¼0.18), and -4.54 mm Hg for DBP (P¼0.009) favoring RDN. Sensitivity analysis including trials with homogenous antihypertensive medical treatment protocol among the RDN and controls showed significant reductions in office systolic and diastolic BP at 6 months favoring RDN (mean difference -14.6; 95% CI -26.28, -2.92; P¼0.01), (mean difference -6.06; 95% CI -9.60, -2.53; P<0.001), respectively. There was no significant difference in terms of heart rate, kidney function, myocardial infraction, stroke, or hypertensive emergency.
CONCLUSIONS RDN is associated with significant 24-hour ambulatory and office based reduction in both systolic and diastolic blood pressure compared to pharmacological treatment alone. Renal denervation is safe and may have a potential role as an adjunct treatment in patients with resistant hypertension.
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TCT-766 Sub-acute Safety and Efficacy Evaluation of a Single versus Double Treatment Cycles of a Monopolar Radiofrequency Catheter-Based Renal Nerve Ablation and its Chronic Evolution in a Large Animal Model
Armando Tellez, 1 Atsushi Sakaoka, 2 Bradley Hubbard, 3 Irena K. Brants, 3 Krista N. Dillon, 1 Dane A. Brady, 1 Chandan Devireddy, 4 Felix Mahfoud, 5 Serge D. Rousselle 1 1 Alizee Pathology, Thurmont, MD; 2 Terumo Corporation, Kanagawa, Japan; 3 Translational Testing and Training (T3) Laboratories, Atlanta, GA; 4 Emory University, Atlanta, GA; 5 Saarland University Hospital, Homburg/Saar, Germany BACKGROUND Transcatheter renal denervation (RDN) therapy has emerged as a therapeutic option for patients diagnosed hypertension resistant to pharmacologic therapy. We aimed to evaluate the effects of radiofrequency treatment (RF) delivered by the Terumo IberisÔ catheter in a large animal model. Additionally, as a secondary end point, we aimed to determine the safety implications of delivery of one cycle versus two cycles of RF ablations.
METHODS 22 domestic swine were enrolled. 18 animals underwent RDN, performed bilaterally; 4 remained untreated as naïve controls for norepinephrine levels (NE) only. Renal arteries were randomized to receive a single cycle of 120 seconds (n¼24) treatment and were followed for 7, 30 and 90 days. 8 renal arteries received 2 treatment cycles (240 seconds total) and were followed for 7 days only. 3 arteries were untreated. Renal cortical samples from the single-cycle treatment group were harvested for NE evaluation at each time point. All renal arteries were harvested for histology and immunohistochemical (IHC) evaluation.
RESULTS All renal arteries were suitable for RF therapy by angiography. The characteristic "notches" post-RF were observed in all treated arteries. At follow up, all arteries demonstrated no luminal obstruction with a TIMI 3 flow. The NE assay showed a 70% decrease in NE levels (76.68AE57.87 ng/g) at 7 days post RDN, 81% significant decrease at 30 days (49.05AE45.81 ng/g), and 51% decrease at 90 days (12.7AE73.2 ng/g) compared to control (254.1AE54.1 ng/ g). Histologically, the thermal effect in the perivascular tissue extended from an average of 40% to a complete (100%) circumferential involvement with a depth reaching up to 8 mm. The primary histological and IHC feature at 7 days was nerve necrosis with consequent nerve atrophy distal to the RF treated level; the arterial wall showed complete re-endothelialization and hyalinization of the media (thermal coagulation necrosis). At 30 days, necrosis was no longer prominent and was replaced by healing changes of fibrosis. Neuromatous regeneration was apparent at 30 days at RF treated levels, a change characterized by disorganized sprouting of neuroid fibers within the thickened perineurium. At 90 days these features progressed to become more conspicuous. There were no appreciable differences in depth and circumferential extent of RF injury between one and two cycle treatment groups.
CONCLUSIONS The Terumo IberisÔ RDN system was demonstrated to be safe following single or double-cycle RF ablation. NE decrease following RDN was demonstrated at 7, 30, and 90 days compared to naïve controls, suggesting efficient nerve ablation with the device as intended for human use. BACKGROUND The blood pressure (BP) response to renal denervation (RDN) is highly variable. In addition, the changes in renal artery (RA) dimensions induced by RDN have rarely been quantified and never been related to BP changes.
METHODS We investigated RAs of 16 patients (7 females, 11 diabetics, mean age 62.6 years) pre and post RDN (Symplicity Flex in 9 pts, Symplicity Spyral in 7 pts; both Medtronic Inc) with intravascular ultrasound (Atlantis pro, Boston Scientific iLab). IVUS images were analyzed with QCU-CMS research software (LUMC) yielding global measures of RA size (RA vessel volume VV, lumen volume LV, wall volume WV), and measures of most pronounced focal changes (minimum and maximum vessel area VA, lumen area LA and wall burden WB) - Figure. Patients were followed with office and 24 hour blood pressure monitoring at month 1, 3, 6, and 12.
RESULTS Pre RDN, 24 hour BP was 153/88 mm Hg, mean number of ablation points was 11.3 (SD 3.4). After 1, 3, 6, and 12 months, 24 hour BP decreased by 12/7, 6/4, 17/9, and 21/11 mm Hg, respectively. RDN induced a non-significant decrease in RA vessel volume of 5.6 (SD 9.8) %, a significant decrease of RA lumen volume of 8.8 (SD 10.7)%, and a non-significant increase of RA wall volume of 6.1 (SD 10.9) %. Max and min LA decreased significantly by 7.3 (SD 9.4) and 10.5 (14.3) %, respectively, as did min VA by 7.1 (12.5) %. Max vessel area and min and max wall burden did not change significantly. Women had smaller RAs, which was related to their lower body height. Changes in RA size were similar between men and women, as were changes in blood pressure. ABPM-based BP change at 1 (SBP, DBP), 3 (SBP, DBP), 6 (DBP) and 12 (DBP) months was significantly and directly related to changes in min LA and min VA (correlation coeffficients 0.63-0.80, p-values 0.002-0.02). At 1 year, decrease in SBP was related to increase in wall volume post RDN (r¼ -0.88, p¼0.004). Patients with a decrease in minimal VA post RDN above the median had a significantly better BP response at 1 and 3 months. Patients with an increase in WV post RDN had a significantly better SBP response at 6 and 12 months.
CONCLUSIONS RDN leads to effects on RA dimensions (decrease in vessel and lumen size, increase in wall thickness), which can be quantified by IVUS. A higher degree of changes may be associated with a better BP response to the procedure. BACKGROUND Renal artery RF ablation is under investigation for the treatment of hypertension. Recent research suggests lesion anatomic placement may impact efficacy of RF catheter renal ablation. Due to the closer proximity of renal sympathetic nerves in the distal vessel segments, it has been suggested that treatment of the renal artery branches might help to reduce variability in efficacy. However, it is unclear whether focused distal treatment of the main renal artery is as effective as branch þ main renal artery treatment. This study was initiated to investigate the overall performance of two RF renal nerve ablation systems as well as ablation anatomic location within the main renal and or bifurcations.
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METHODS Sixteen swine were treated unilaterally with either 8 lesions in the branch renal arteries (BA) or 8 in the branch þ 4 in the main renal artery (MA) with the Medtronic Spyral(TM) catheter (SP) or in the MA alone with the St. Jude Medical EnligHTN(TM) catheter (EN) in one of four arms: 1) SP8 -8 BA lesions, 2) SP12 -8 BA þ 4 MA lesions, 3) EN8 -8 MA lesions, or 4) EN12 -12 MA lesions. Treatment followed manufacturers' instructions for use & were performed by one proceduralist. All lesions in the MA were placed as distal as possible without overlapping treatment sites. Animals were euthanized at 14 days with each serving as its own control for norepinephrine (NE) analysis.
RESULTS A total of 162 lesions (EN n¼80 & SP n¼82) were created. All results are given as mean & StDev unless stated otherwise. Each arm showed statistical significant changes in NE (ng/g) between treated kidneys vs. untreated contralateral control (C): EN8 125.0 AE159.0 vs. EN8-C 461.2 AE84.1 (P¼0.010), EN12 22.9 AE14.7 vs. EN12-C 492.8 AE62.9 (P<0.001), SP8 106.1 AE78.4 vs. SP8-C 438.5 AE66.4 (P<0.001), SP12 72.5 AE79.8 vs. SP12-C 411.155 AE96.7 (P¼0.002). There were no statistically significant differences in tissue NE % reductions across each arm based on catheter, anatomic location, & number of lesions: EN8 -74 AE34%, EN12 -95 AE3%, SP8 -76 AE16%, SP12 -82 AE17% (P¼0.494). Nerve count based on anatomic location & lesion pathology results will be presented.
CONCLUSIONS There was no difference observed between the % reduction in tissue NE levels comparing main renal artery distal treatment with the EnligHTN catheter & branch þ main renal artery treatment with the Spyral catheter. 
